299. 嚢胞性線維症 Cystic fibrosis Clinical trials / Disease details
臨床試験数 : 1,695 / 薬物数 : 1,527 - (DrugBank : 268) / 標的遺伝子数 : 111 - 標的パスウェイ数 : 174
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05095246 (ClinicalTrials.gov) | March 8, 2022 | 27/8/2021 | A Study of Inhaled KB407 for the Treatment of Cystic Fibrosis | A Phase I Study of Inhaled KB407, a Replication-Incompetent, Non-Integrating Vector Expressing Human Cystic Fibrosis Transmembrane Conductance Regulator (CFTR), for the Treatment of Cystic Fibrosis | Cystic Fibrosis | Biological: KB407 (Nebulization) | Krystal Biotech, Inc. | Novotech (Australia) Pty Limited | Recruiting | 18 Years | N/A | All | 13 | Phase 1 | Australia |